In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HeartPort: Still Beating

Executive Summary

Once one of the highest-flying medical device companies of the 1990s, the last couple of years have not been easy for minimally-invasive cardiac surgery company, HeartPort Inc. The company developed an innovative approach to minimally-invasive bypass and heart valve surgery, one that incorporated the use of CPB (coronary-pulmonary bypass) in a closed procedure on the theory that CPB is the gold standard in open procedures. The problem is, no one wanted it. (Most surgeons would like to eliminate CPB from open procedures, if possible.) As adoption rates of its technology lagged far behind the company's projections, HeartPort became a fading star. But company officials insist HeartPort's fortunes are turning around.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts